Notícias e Atividades da Spur Therapeutics

A Spur Therapeutics pertence à Syncona.

Syncona é uma das ...

• FTSE 350;
• TOB Iconic 10,000.

Syncona é uma empresa listada sob o símbolo SYNC (GB).

Syncona tem presença direta em 3 países.

Syncona possui 11 subsidiárias incluindo Anaveon, Autolus Therapeutics e Beacon Therapeutics.

Eles estão dentro:

• Biotecnologia83%
• Holding8%
• Outro8%

Veja o organograma con seus 22 executivos principais

Biografias mais buscadas da Spur Therapeutics

• Michael Parini, Chief Executive Officer and Executive Director (be...
• Samantha Roberts, Director
• Chris Hollowood, Chairman of the Board (becomes Director on Aug 1 ...

Recentes movimentos de executivos em Spur Therapeutics

• Samantha Roberts atualmente Executive Partner, Syncona, passará a Director em 31 de jul. de 2026  (Notícia publicada em 17 de julho de 2026).
• Henning Stennicke atualmente Chief Scientific Officer, passará a Chief Operating Officer em 1 de ago. de 2026  (Notícia publicada em 15 de julho de 2026).
• Michael Parini atualmente Chief Executive Officer and Executive Director, passará a Chairman of the Board em 1 de ago. de 2026  (Notícia publicada em 15 de julho de 2026).

Clique aqui para ver outras movimentos em Spur Therapeutics

Recentes movimentos de executivos em Syncona

• Norman Crighton ingressará na Companhia como Independent Non-Executive Director em 1 de jul. de 2026  (Notícia publicada em 17 de junho de 2026).

Criar um alerta
para seguir os movimentos de executivos da Spur Therapeutics.

Syncona possui 2.429 concorrentes concorrentes Lonza (Suíça), Vertex Pharmaceuticals (Estados Unidos) e Eurofins (Luxemburgo).

Popular M&A news in Biotecnologia

• Eli Lilly has announced the acquisition of AtaiBeckley  (publicado em 17 de julho de 2026).
• GSK adquiriu Nuvalent (publicado em 17 de julho de 2026).
• Clearside Biomedical has gone out of its bankruptcy protection  (publicado em 15 de julho de 2026).

Outros contatos sugeridos na indústria do Biotecnologia

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer da Inceptive
• Jan Van de Winkel - President and Chief Executive Officer da Genmab
• Patrick Enright - Director da CuraSen Therapeutics

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de Spur Therapeutics

• Spur Therapeutics Presents Clinical Insights on Bone Disease Impact of FLT201 in Adults with Gaucher Disease Type 1
• Spur Therapeutics To Present New Clinical Data on FLT201 for Gaucher Disease during the IWGGD 2026 Symposium
• Spur Therapeutics Presents New Phase 1/2 Data on Its Gene Therapy Candidate in Gaucher Disease at 22nd Annual WORLDSymposium™
• Spur Therapeutics Announces Platform and Poster Presentations Highlighting New Clinical Data for FLT201 in Gaucher Disease at Upcoming WORLDSymposium™
• Spur Therapeutics Presents Updated Phase 1/2 Data on Its Gene Therapy Candidate in Gaucher Disease at ESGCT 32nd Annual Congress
• Spur Therapeutics to Present New Clinical Data on Its Gene Therapy Candidate in Gaucher Disease at Upcoming ESGCT Annual Congress
• Spur Therapeutics Presents Positive New Preclinical Data on Its Gene Therapy Candidate for GBA1 Parkinson’s Disease at 2025 GBA1 Meeting
• Spur Therapeutics Publishes Preclinical Proof-of-Concept Data for FLT201, its Clinical-Stage Gene Therapy Candidate in Gaucher Disease
• Spur Therapeutics Announces Oral and Poster Presentations Highlighting Data from Clinical and Preclinical Programs at Upcoming ASGCT Annual Meeting
• Spur Therapeutics to Participate in Citizens JMP 2025 Life Sciences Conference
• View more press releases Close

Redes sociais sobre Spur Therapeutics

• Spur Therapeutics na Wikipedia, Google News e Yahoo Finance
• Spur Therapeutics na LinkedIn, X (Twitter) e YouTube